Dr. Ronne Yeo is a biotech investor, inventor and entrepreneur with a track record in leading R&D in biotech companies. Ronne joined Esco Ventures in 2016, the corporate investment arm of Esco Group and predecessor of EVX Ventures, and has since been identifying and evaluating investment opportunities in innovative drugs. Ronne played key roles towards developing EVX Ventures’ capabilities in biotech venture creation. Working alongside XQ Lin and leveraging his scientific training in extracellular vesicles, he became a key founding member for Carmine Therapeutics, EVX Ventures’ flagship company and first to expand R&D operations into Boston MA. Carmine is pioneering non-viral gene therapy based on red blood cell extracellular vesicles, with Professors Harvey Lodish, Minh Le and Jiahai Shi as scientific co-founders. As Founding Vice President of Discovery, Ronne built and led the R&D team to create the Red Cell EV Gene Therapy (REGENT™) Platform to enable targeted delivery of large, complex nucleic acid cargoes, leading to a research collaboration with Takeda Pharmaceuticals in a deal worth over USD 900M, in a span of a little over a year since its founding. Carmine went on to become named as one of FierceBiotech’s “Fierce 15” companies of 2020, designating it as one of the most promising private biotechnology companies in the world. Ronne continued his role as head of R&D supervising research in both the US and Singapore sites until November 2021 when he moved on to a new EVX Ventures portfolio company, Carcell Biopharma, as cofounder and Chief Scientific Officer. During his stint at Carmine, Ronne was the inventor of key patent families and several know-hows that underlie its non-viral gene therapy programs.
Ronne conceptualized and pioneered EVX Ventures’ initiatives to ensure a proprietary dealflow for investment or company creation. These are the Morphosis Fellowship program founded in 2018 and the PLATINUM grant launched in 2020.
Prior to joining EVX Ventures, Ronne was Senior Research Fellow at A*STAR Institute of Medical Biology, where he was involved in the preclinical development of mesenchymal stem cell extracellular vesicles - a novel therapeutic modality targeting cardiovascular and immune disorders, currently being developed by A*STAR spin-off Paracrine Therapeutics. Ronne obtained his PhD from NUS Graduate School - Integrative Sciences and Engineering Program (ISEP), and a BSc in Biological Sciences from Nanyang Technological University.